Skip to main content
Equibles
NTLA logo

NTLA · Intellia Therapeutics, Inc.

Track NTLA — free

Use NTLA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$12.74 +0.06 (+0.47%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$1.78B
Shares
140.13M

NTLA metrics

64 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$12.74
Market cap
$1.78B

Price action

19 metrics
Price change (1W)
-1.0%
Price change (30D)
+13.3%
Price change (3M)
-5.9%
Price change (6M)
-5.2%
Price change (YTD)
+41.7%
Price change (1Y)
+9.6%
Trailing year
Price change (5Y)
-92.8%
52-week high
$27.98
52-week low
$8.04
Change from 52-week high
-54.5%
Change from 52-week low
+58.5%
Annualized volatility
99.0%
Beta
2.4
RSI (14D)
52.1
Price vs SMA 50
-1.4%
Price vs SMA 200
+1.5%
Avg volume (3M)
4.65M
Relative volume
0.6
Average dollar volume
$62.95M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
140.13M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
29.9×
reciprocal yield 3.3%
P / book
2.4
reciprocal yield 41.0%
FCF yield
-19.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-22.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
-711.7%
Trailing 12 months
Net margin
-672.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$423.48M
Net income (TTM)
−$399.98M
Trailing 12 months
Diluted EPS (TTM)
$-3.34
FCF margin
-586.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-8.29

Growth

11 metrics
Revenue growth YoY
-46.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$59.51M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+28.7%
Year over year · more shares
Revenue CAGR (3Y)
+9.1%
Revenue CAGR (5Y)
+3.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-55.0%
Return on assets
-46.7%
Debt / equity
—
Current ratio
6.6
EBITDA (TTM)
−$414.41M
Free cash flow (TTM)
−$348.69M
Quick ratio
6.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$437.76M
Latest balance sheet
Cash & equivalents
$106.13M
Total assets
$857.16M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$346.64M
Capital expenditures (TTM)
$2.04M
R&D (TTM)
$346.73M
SG&A (TTM)
—
Stock compensation (TTM)
$67.90M
R&D / revenue
582.7%
Stock compensation / revenue
114.1%

Ownership (13F)

3 metrics
13F filers
334
13F filer change QoQ
+23
Institutional ownership
105.7%

Short interest

3 metrics
Short interest
32.0%
Latest settlement · 13.2 days to cover
Days to cover
13.2d
Short-squeeze score
67 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$506,570
Insider-sentiment score
43 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1652130 CUSIP 45826J105 13F (30d) 241 filings 233 filers Visit website Investor relations